menu
    • menu

    Company profile for InxMed

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Yingshi Biology is a cutting-edge biotechnology company with disease biology as the source of innovation. It is committed to creating the "best combination therapy drug development strategy", establishing a platform with rapid clinical transformation and proof-of-concept capabilities, and becoming a new drug The R & D 2.0 era is based on China's leading global new drug research and development company.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    InxMedChina Flag
    Country
    Country
    China
    Address
    Address
    Huamao Office Building, No. 79 Jianguo Road, Chaoyang District, Beijing
    Telephone
    Telephone
    010-85887500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.inxmed.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    InxMed’s Ifebemtinib Receive Breakthrough for NSCLC in China
    InxMed’s Ifebemtinib Receive Breakthrough for NSCLC in China

    21 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/inxmed-fak-inhibitor-ifebemtinib-received-breakthrough-therapy-designation-by-china-national-medical-products-administration-for-first-line-non-small-cell-lung-cancer-nsclc-with-kras-g12c-mutation-302312546.html

    PR NEWSWIRE
    21 Nov 2024
    Share Share
    InxMed Presents Data On Improving ADC Therapeutic At World ADC
    InxMed Presents Data On Improving ADC Therapeutic At World ADC

    07 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/inxmed-presents-data-regarding-potential-novel-way-to-improve-therapeutic-window-of-adc-by-ifebemtinib-and-fic-adc-at-15th-annual-world-adc-302299542.html

    PR NEWSWIRE
    07 Nov 2024
    Share Share
    InxMed Positive Ifebemtinib Garsorasib Data In KRAS G12C NSCLC
    InxMed Positive Ifebemtinib Garsorasib Data In KRAS G12C NSCLC

    30 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/inxmed-reports-positive-phase-ibii-results-for-ifebemtinib-in-combination-with-garsorasib-in-non-small-cell-lung-cancer-nsclc-with-kras-g12c-mutation-302157162.html

    PR NEWSWIRE
    30 May 2024
    Share Share
    InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
    InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs

    19 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/inxmed-enters-license-agreement-with-escugen-to-develop-next-generation-adcs-302019573.html

    PR NEWSWIRE
    19 Dec 2023
    Share Share
    InxMed Releases Data Demonstrating Ifebemtinib Trending Toward Survival Benefit
    InxMed Releases Data Demonstrating Ifebemtinib Trending Toward Survival Benefit

    22 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/inxmed-releases-data-demonstrating-ifebemtinib-in10018-trending-toward-survival-benefit-at-esmo-2023-301963834.html

    PR NEWSWIRE
    22 Oct 2023
    Share Share
    InxMed Presents Data at 14th World ADC Highlighting Synergy of IN10018
    InxMed Presents Data at 14th World ADC Highlighting Synergy of IN10018

    18 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/inxmed-presents-new-data-at-14th-annual-world-adc-highlighting-synergy-of-in10018-with-adcs-and-novel-stroma-targeting-pipeline-301960551.html

    PR NEWSWIRE
    18 Oct 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search